Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States.
about
The Effect on Treatment Adherence of Administering Drugs as Fixed-Dose Combinations versus as Separate Pills: Systematic Review and Meta-AnalysisAn Illustration of Inverse Probability Weighting to Estimate Policy-Relevant Causal EffectsDevelopment of Hematopoietic Stem Cell Based Gene Therapy for HIV-1 Infection: Considerations for Proof of Concept Studies and Translation to Standard Medical PracticeThe cost-effectiveness of improved hepatitis C virus therapies in HIV/hepatitis C virus coinfected patients.Antiretroviral drug costs and prescription patterns in British Columbia, Canada: 1996-2011.French 2013 guidelines for antiretroviral therapy of HIV-1 infection in adults.Quality Attributes and In Vitro Bioequivalence of Different Brands of Amoxicillin Trihydrate Tablets.Setting Performance Standards for a Cost-Effective Human Immunodeficiency Virus Cure Strategy in South Africa.Modeling the cost-effectiveness of HIV treatment: how to buy the most 'health' when resources are limited.HIV cure strategies: how good must they be to improve on current antiretroviral therapy?Cost-effectiveness of rapid hepatitis C virus (HCV) testing and simultaneous rapid HCV and HIV testing in substance abuse treatment programsA methodological review of models used to estimate the cost effectiveness of antiretroviral regimens for the treatment of HIV infection.Cost-effectiveness analysis of brief and expanded evidence-based risk reduction interventions for HIV-infected people who inject drugs in the United StatesThe lifetime medical cost savings from preventing HIV in the United States.The clinical role and cost-effectiveness of long-acting antiretroviral therapyResource utilisation and cost of ambulatory HIV care in a regional HIV centre in Ireland: a micro-costing study.Projected Lifetime Healthcare Costs Associated with HIV Infection.Partner Notification for Reduction of HIV-1 Transmission and Related Costs among Men Who Have Sex with Men: A Mathematical Modeling Study.Cost-Effectiveness of Single- Versus Generic Multiple-Tablet Regimens for Treatment of HIV-1 Infection in the United States.Investigation of Efavirenz Discontinuation in Multi-ethnic Populations of HIV-positive Individuals by Genetic Analysis.Cost-Effectiveness of Dolutegravir in HIV-1 Treatment-Naive and Treatment-Experienced Patients in Canada.Meta-Analysis of Studies Comparing Single and Multi-Tablet Fixed Dose Combination HIV Treatment RegimensPrioritizing HIV comparative effectiveness trials based on value of information: generic versus brand-name ART in the USThe Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States.Societal Implications of Health Insurance Coverage for Medically Necessary Services in the U.S. Transgender Population: A Cost-Effectiveness Analysis.Cost-effectiveness of CYP2B6 genotyping to optimize efavirenz dosing in HIV clinical practice.Patients' Willingness to Take Multiple-Tablet Antiretroviral Therapy Regimens for Treatment of HIVCost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States.Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society-USA PanelLower pill burden and once-daily antiretroviral treatment regimens for HIV infection: A meta-analysis of randomized controlled trials.Practical considerations in gene therapy for HIV cure.Cost-effectiveness of dolutegravir/abacavir/lamivudine in HIV-1 treatment-Naive (TN) patients in France.Generic substitution of antiretrovirals: patients' and health care providers' opinions.Addressing discriminatory benefit design for people living with HIV: a California case study.Dolutegravir as maintenance monotherapy: first experiences in HIV-1 patients.Potential impact on HIV incidence of higher HIV testing rates and earlier antiretroviral therapy initiation in MSM.Impact of Cigarette Smoking and Smoking Cessation on Life Expectancy Among People With HIV: A US-Based Modeling Study.The Impact of State AIDS Drug Assistance Policies on Clinical and Economic Outcomes of People With HIV.A Regional Drug and Therapeutics Committee-led Intervention to Reduce the Hospital Costs of Expensive HIV Drugs.Virological responses to lamivudine or emtricitabine when combined with tenofovir and a protease inhibitor in treatment-naïve HIV-1-infected patients in the Dutch AIDS Therapy Evaluation in the Netherlands (ATHENA) cohort.
P2860
Q26865049-78D305F3-88DC-4C9C-BDD7-07B353DD39BDQ28386534-AA9E9413-E029-467E-874D-03807EAC6B06Q29036869-ED3E8BB7-8FA7-4567-8339-959EF2CD5275Q33710740-DBF69AED-1B10-4D09-B004-D5C393475010Q33713411-BC83833D-55EB-4C82-A6C7-75628A6D8D24Q33775397-8A2F84A8-E6BE-4651-873B-50BD9FCD8BCFQ33850443-E93722AF-0D6D-4D23-999E-AE154DA04A96Q33851741-0B6144B2-3B15-41D4-ACEF-D96B8267E694Q33854542-BD40E700-8822-4F64-AFAB-F942293A6FD6Q34514601-83E9C8BB-6C02-4D35-B89E-87A3C9237524Q34735072-C9B9DA19-01E1-46F6-AD05-78688041E774Q35043404-17D19A24-0148-4E35-A6A4-A0F9C23F4E14Q35058786-37517429-1197-4BEE-96A5-EB573DB7B5A6Q35177401-4C203888-0EA3-4D46-ACFE-EF0348CD3034Q35197271-B49DC7DA-AA67-4F0C-93C3-B0270E3DF321Q35368446-7731BCF2-2BA7-41A0-9B95-9B792E918EC0Q35526724-BC39D2E5-CA79-457B-8DB5-E5C96DBF8FD7Q35837001-862E2B42-5876-4BEA-851A-87D21D0450EFQ35903617-5ECBED78-0ADB-4902-A587-83BF81053D4AQ35947529-13742662-F267-499A-B2EB-9E8E0D3FD71CQ36073384-C7A0E9A2-8025-4157-BC07-E46489AF5B93Q36206941-1FC4E7B6-15E7-42EB-8543-44463F2F1D17Q36479518-4669F229-B9E5-4C5A-9F47-0DB5DCE9F5BCQ36635714-CB4CE5AF-FA7A-4B0F-820C-EA6F1D2E013CQ36717555-2C24B7EC-27A3-42AD-890E-A21CE234FE6BQ36801543-51DB82AB-F3FC-4E36-8485-A74CD637099AQ37022939-42F0AF0F-0059-42F4-BF9C-9A5AD99AAE1BQ37103050-8CD0CF8A-CE36-4263-9A28-C02056127902Q37234729-9D630068-2EC8-4DD8-94F4-9DA3696F1006Q37696578-8B345143-7C5D-47D4-82BF-4FD924E28819Q38180645-10B1DC42-26FE-4578-BEF7-D5E740486DDAQ38662696-2649172C-A716-481E-8695-21BE81CBF7D9Q38717415-8176F7B6-CF6E-49A4-B07A-E4BE2E7EDB55Q38732649-097EEB21-0306-4879-B743-53514E33A869Q38906639-F69A9CF5-DFBB-41DC-8213-F63A47D96C29Q38963785-19280A3A-E208-49AF-AB1F-A03CE92AF301Q39213747-BF8C3BF7-3598-4BB2-A1F7-A293C86CBBB3Q40355570-8BD0347E-9E18-4512-AD90-E031EF721359Q40743211-E3F50B21-C689-4423-9E13-B7C800CD8340Q40806577-2F54BE9A-6AF7-4891-999D-4B9C7AD2B31D
P2860
Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Economic savings versus health ...... therapy in the United States.
@en
type
label
Economic savings versus health ...... therapy in the United States.
@en
prefLabel
Economic savings versus health ...... therapy in the United States.
@en
P2093
P2860
P50
P1476
Economic savings versus health ...... therapy in the United States.
@en
P2093
A David Paltiel
Bruce R Schackman
Pamela P Pei
Paul E Sax
Yoriko M Nakamura
P2860
P356
10.7326/0003-4819-158-2-201301150-00002
P407
P577
2013-01-01T00:00:00Z